TRAIL (C92B9) Rabbit mAb (PE Conjugate) #37020
- F
Supporting Data
REACTIVITY | H |
SENSITIVITY | Endogenous |
MW (kDa) | |
Source/Isotype | Rabbit IgG |
Application Key:
- F-Flow Cytometry
Species Cross-Reactivity Key:
- H-Human
Product Information
Product Description
Product Usage Information
Application | Dilution |
---|---|
Flow Cytometry (Fixed/Permeabilized) | 1:50 |
Storage
Protocol
Specificity / Sensitivity
TRAIL (C92B9) Rabbit mAb (PE Conjugate) detects endogenous levels of total human TRAIL protein.
Species Reactivity:
Human
Source / Purification
Monoclonal antibody is produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Lys60 of human TRAIL, within the extracellular region of the protein.
Background
Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL), also referred to as Apo2 ligand, first identified based on its sequence homology to TNF and Fas/Apo ligand is a member of the TNF family of cytokines and either exists as a type II membrane or soluble protein (1,2). TRAIL induces apoptosis in a variety of transformed cell lines and plays a role in anti-tumor and anti-viral immune surveillance (3). TRAIL signals via binding with death receptors DR4 (TRAIL-R1) (4) and DR5 (TRAIL-R2) (5-8) which can trigger apoptosis as well as NF-κB activation (7,9). Death domains on these receptors leads to the recruitment of a death-induced signaling complex (DISC) leading to caspase-8 and subsequent caspase-3 activation. In addition, TRAIL binds with decoy receptors DcR1 (TRAIL-R3) (6,8,10,11) and DcR2 (TRAIL-R4, TRUNDD) (12,13) which lack the functional cytoplasmic death domain antagonizing TRAIL-induced apoptosis. Osteoprotegerin (OPG) has also been identified as receptor capable of inhibiting TRAIL-induced apoptosis (14). The selectivity of soluble TRAIL at triggering apoptosis in transformed cells as compared to normal cells has led to its investigation as a potential cancer therapeutic (15,16).
- Wiley, S.R. et al. (1995) Immunity 3, 673-82.
- Pitti, R.M. et al. (1996) J Biol Chem 271, 12687-90.
- Almasan, A. and Ashkenazi, A. Cytokine Growth Factor Rev 14, 337-48.
- Pan, G. et al. (1997) Science 276, 111-3.
- Walczak, H. et al. (1997) EMBO J 16, 5386-97.
- MacFarlane, M. et al. (1997) J Biol Chem 272, 25417-20.
- Chaudhary, P.M. et al. (1997) Immunity 7, 821-30.
- Schneider, P. et al. (1997) FEBS Lett 416, 329-34.
- Shetty, S. et al. (2002) Apoptosis 7, 413-20.
- Sheridan, J.P. et al. (1997) Science 277, 818-21.
- Degli-Esposti, M.A. et al. (1997) J Exp Med 186, 1165-70.
- Pan, G. et al. (1998) FEBS Lett 424, 41-5.
- Marsters, S.A. et al. (1997) Curr Biol 7, 1003-6.
- Kelley, S.K. et al. (2001) J Pharmacol Exp Ther 299, 31-8.
- Walczak, H. et al. (1999) Nat Med 5, 157-63.
- Ashkenazi, A. et al. (1999) J Clin Invest 104, 155-62.
Limited Uses
Except as otherwise expressly agreed in a writing signed by a legally authorized representative of CST, the following terms apply to Products provided by CST, its affiliates or its distributors. Any Customer's terms and conditions that are in addition to, or different from, those contained herein, unless separately accepted in writing by a legally authorized representative of CST, are rejected and are of no force or effect.
Products are labeled with For Research Use Only or a similar labeling statement and have not been approved, cleared, or licensed by the FDA or other regulatory foreign or domestic entity, for any purpose. Customer shall not use any Product for any diagnostic or therapeutic purpose, or otherwise in any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST products or services, (c) not alter or remove from the Products any trademarks, trade names, logos, patent or copyright notices or markings, (d) use the Products solely in accordance with CST Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.